Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS ADVANCES 1KG SCALE-UP OF B4 PRECURSOR SUPPORTING ONC010 MANUFACTURING AND CLINICAL DEVELOPMENT PROGRAM

Further to the news release dated May 19, 2026, the kilogram-scale manufacturing activities for the B4 precursor component supporting the development of ONC010, Onco-Innovations Ltd.'s lead nanoparticle-formulated polynucleotide kinase phosphatase inhibitor technology, have advanced.

The milestone was achieved through the company's continuing chemistry, manufacturing and controls collaboration with Dalton Pharma Services, and represents an important step in scaling the manufacturing process required to support future formulation development, engineering batches, good manufacturing practice production and planned clinical studies.

B4 is a critical precursor used in the synthesis pathway for ONC010 and forms an essential component of the company's broader manufacturing strategy. Recent scale-up activities resulted in the successful production and isolation of approximately 952 grams of B4 material, representing a meaningful increase in manufacturing scale, while maintaining quality standards necessary for continued development activities.

The company believes this achievement further validates the scalability of its manufacturing approach and supports continuing efforts to establish a robust and reproducible production process for future clinical supply.

"This milestone represents another important advancement in the maturation of our ONC010 manufacturing platform. Successfully scaling the production of key precursor materials is essential to building a reliable and scalable supply chain capable of supporting future clinical development. The continued progress achieved by our manufacturing partners demonstrates the strength of our integrated development strategy and reinforces our commitment to advancing ONC010 toward the clinic," said Thomas O'Shaughnessy, chief executive officer of Onco-Innovations.

The B4 scale-up milestone forms part of a broader integrated manufacturing program that includes precursor synthesis, active pharmaceutical ingredient production, polymer development, nanoparticle formulation, analytical characterization and future GMP manufacturing activities. The company's manufacturing ecosystem currently includes Dalton Pharma Services and Nucro-Technics, each contributing specialized expertise across critical development work streams.

"Manufacturing readiness is a fundamental component of successful clinical translation. The advancement of kilogram-scale precursor production strengthens the foundation of the ONC010 program and supports the company's broader objective of delivering a clinically viable and scalable therapeutic candidate. As we continue progressing through IND-enabling activities, these manufacturing achievements contribute directly to reducing development risk and supporting future regulatory readiness," stated Dr. Islam Mohamed, chief medical officer of Onco-Innovations.

The company also announces that it has engaged InvestorBrandNetwork, an arm's-length third party, to provide market awareness, corporate communications and digital media services, including editorial content, press release recap-style coverage, newsletter coverage, social media relations support, podcast-related distribution and syndication through IBN's investor-focused media network. The company will pay IBN an aggregate cash fee of $76,500 (U.S.) for the services. The company also announces that it has obtained the return of an unused balance of $80,000 (U.S.) from its prior market awareness engagement with another provider (see company press release dated May 1, 2026). The company intends to allocate the returned unused balance toward the consideration. The services are scheduled to run until Sept. 30, 2026, or budget exhaustion, and are structured to allow for continuing evaluation, and, accordingly, may be shortened or extended at the discretion of the company. No securities have been provided to IBN or its principals as compensation for the services.

About ONC010

ONC010 is a novel nanoparticle-formulated inhibitor of polynucleotide kinase phosphatase, a key DNA damage repair enzyme. The program is being developed to exploit vulnerabilities in cancer cells dependent on DNA repair pathways and is intended to provide a differentiated therapeutic approach for patients with difficult-to-treat malignancies.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.